# Insulin glargine + Lixisenatide

## Soliqua inj 100 Unit/50mcg/mL 3mL Pen

| TAH Drug Code      | [ISLQ](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ISLQ)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who have inadequate control with (1) metformin in combination with another oral antidiabetic agent or metformin in combination with basal insulin (daily dose <60 units), (2) metformin in combination with a glucagon-like peptide-1 (GLP-1) receptor agonist or metformin in combination with another oral antidiabetic agent and a GLP-1 receptor agonist, or (3) basal insulin (daily dose less than 60 units) or lixisenatide.                                                                                                                                                                                                                                                                                                                                      |
| Dosing             | Administer once daily, injected within 1 hour before the same meal each day. Discontinue basal insulin or glucagon-like peptide-1 (GLP-1) receptor agonist therapy prior to initiation. Initial dose: (1) If no previous use of insulin: 10 units (10 units/5 mcg). (2) If using <20 units of **insulin glargine (100 units/ml)**: 10 units (10 units/5 mcg). (3) If using 20-30 units of **insulin glargine (100 units/ml)**: 20 units (20 units/10 mcg). Max: 40 units/day (insulin glargine 40 units + lixisenatide 20 mcg). **Note**: If a different basal insulin is used: - If the basal insulin is given twice daily or if daily insulin glargine (300 units/mL) is used, the previous total daily dose should be reduced by 20% as the starting dose for Soliqua. - For any other basal insulin, the calculation method is the same as for insulin glargine (100 units/mL). |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Contraindications  | History of serious hypersensitivity to insulin glargine, lixisenatide, or any component of the formulation; during episodes of hypoglycemia.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Adverse Effects    | Common: Diarrhea (7%), Nausea (10%), Headache (5.4%), Nasopharyngitis (7%), Upper respiratory infection (5.5%) Serious: Hypoglycemia (17.8%), Hypokalemia, Pancreatitis, Cholecystitis, Cholelithiasis, Disorder of gallbladder, Anaphylaxis, Hypersensitivity reaction, Acute injury of kidney, Angioedema                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Pregnancy          | No (Limited) Human Data â€“ Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| More Info          | [UpToDate](https://www.uptodate.com/contents/insulin-glargine-and-lixisenatide-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

